supported by DOD PCRP award W81XWH-16-1-0404(HVH);NIH NCI grant CA166440(HVH).
Prostate cancer(PCa)progression relies on androgen receptor(AR)action.Preventing AR’s ligand-activation is the frontline treatment for metastatic PCa.Androgen deprivation therapy(ADT)that inhibits AR ligand-binding i...